Business Wire

Stallergenes Greer Announces Publication of Positive Results for PALFORZIA® Phase 3 Study in Peanut-allergic Children Aged 1 to 3 Years


Stallergenes Greer, a leading global healthcare company specialising in allergen immunotherapy (AIT), announces the publication of results from the Phase 3 POSEIDON (Peanut Oral Immunotherapy Study of Early Intervention for Desensitization) study in the New England Journal of Medicine Evidence. The study evaluated the efficacy and safety of PALFORZIA [defatted powder of Arachis hypogaea L., semen (peanuts)] in peanut-allergic children aged 1 to 3 years.

The study met the primary endpoint, with the majority of patients treated with PALFORZIA tolerating at least a 600 mg single dose (1,043 mg cumulative) or a 1,000 mg single dose (2,043 mg cumulative) of peanut protein (73.5% and 68.4%, respectively, compared to 6.3% and 4.2% of patients who received placebo, respectively). In addition, the majority of patients treated with PALFORZIA (61.2% compared with 2.1% of placebo-treated patients) tolerated the highest exit double-blind, placebo-controlled exit food challenge (DBPCFC) dose level of 2,000 mg (4,043 mg cumulative), and this proportion was higher for the youngest age group.

PALFORZIA demonstrated a favorable safety profile. Overall, 84.7% of patients on PALFORZIA and 93.8% of patients on placebo completed the study. There were no PALFORZIA-related serious or severe adverse events, and systemic allergic reactions due to any cause were similar between PALFORZIA and placebo-treated patients (8.2% and 8.3%, respectively). Treatment-related systemic allergic reactions occurred in 2% of PALFORZIA-treated patients and 0% of placebo-treated patients.

A 3.5-fold increase in peanut allergy prevalence has been reported in recent years, with 1 to 2% of children in Western countries affected1. Reactions to peanut are potentially life-threatening, accounting for the majority of deaths related to food allergy2.

Through the Poseidon study, we have witnessed a significant shift in how peanut allergy can be managed in the youngest patients,” said George du Toit, M.B., B.Ch., Professor of Pediatric Allergy at Evelina London Children’s Hospital, Guy's and St Thomas' NHS Foundation Trust, King’s College London and study investigator in PALFORZIA clinical trials. “These findings highlight the potential benefit of early intervention for peanut-allergic children aged 1 to 3 years, offering a glimpse of hope for a future where we can alleviate the burden of this condition.”

We are delighted about the results which underscore the clinical significance of PALFORZIA for peanut-allergic toddlers. The results, published in the New England Journal of Medicine Evidence, are truly promising and potentially life-changing for young patients. The recent addition of PALFORZIA, the first standardised treatment for peanut-allergic toddlers, to Stallergenes Greer’s portfolio is testimony to our unwavering commitment to provide patients and the medical community with innovative AIT treatments,” says Amer Jaber, Chief Innovation Officer of Stallergenes Greer.

To read the publication:


POSEIDON (Peanut Oral Immunotherapy Study of Early Intervention for Desensitization, number NCT03736447) is an international, randomized (2:1), double-blind, placebo-controlled Phase 3 study that evaluated the efficacy and safety of PALFORZIA in peanut-allergic children aged 1 to <4 years of age in North America and Europe. The POSEIDON study was completed by Aimmune Therapeutics, part of Nestlé Health Science before Nestlé divested PALFORZIA to Stallergenes Greer in September 2023. Enrollment was based on several entry criteria, including a documented clinical history of peanut allergy, positive skin prick tests and/or elevated blood levels of peanut antibodies, and dose-limiting symptoms after consuming single doses of peanut protein >3 to ≤300 mg in a positive double-blind, placebo-controlled food challenge (DBPCFC). In POSEIDON, patients underwent a dose-escalation period of approximately 22 weeks to reach a dose of 300 mg per day of PALFORZIA or placebo, then continued that dose for approximately six months. At the end of the trial, patients underwent an exit DBPCFC.


PALFORZIA is a complex biologic drug used with a structured dosing approach that builds on a century of oral immunotherapy (OIT) research. With OIT, the specific allergenic proteins are ingested initially in very small quantities, followed by incrementally increasing amounts, that can result in the ability to mitigate allergic reactions to the allergen over time. PALFORZIA is a rigorously developed, pharmaceutical-grade OIT for peanut allergy with a well-defined allergen profile to assure the consistency of every dose, from 0.5 mg (equivalent to 1/600th of a peanut) to 300 mg.

PALFORZIA is not intended for, and does not provide, immediate relief of allergic symptoms. Therefore, this medicinal product is not to be used for emergency treatment of allergic reactions, including anaphylaxis. Self-injectable adrenaline (epinephrine) must be available to the patient at all times.

PALFORZIA is approved by the U.S. Food and Drug Administration (FDA) by the European Medicine Agency (EMA), by the Medicines and Healthcare products Regulatory Agency (MHRA) in the U.K., and by Swissmedic in Switzerland.


Headquartered in Baar (Switzerland), Stallergenes Greer International AG is a global healthcare company specialising in the diagnosis and treatment of respiratory and food allergies through the research, development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer International AG is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France). For more information, visit


  1. Lange L, Klimek L, Beyer K, et al. White paper on peanut allergy. Part 1: epidemiology, burden of disease, health economic aspects. Allergo j Int 2021;30:261-269. DOi: 10.1007 / s40629-021-00189-z.
  2. Bock SA, Muñoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol. 2001;107:191-193.

PALFORZIA: © 2023, Société des Produits Nestlé S.A. or its affiliates

To view this piece of content from, please give your consent at the top of this page.

Contact information

Catherine Kress
Tel: +33 (0)1 55 50 26 05

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

World Green Economy Summit Emphasises the Need for Prompt and Collaborative Action7.12.2023 18:04:00 CET | Press release

Under the patronage of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and during the World Green Economy Summit, a Ministerial Roundtable on Green Economy, was held. It was attended by HE Surangel Whipps Jr., President of the Republic of Palau; HE Patricia Scotland KC, Secretary General of the Commonwealth of Nations; James Grabert Director, Mitigation Division at UNFCCC, and ministers and officials from around the world. This press release features multimedia. View the full release here: World Green Economy Summit emphasises the need for prompt and collaborative action (Photo: AETOSWire) In his inaugural speech, HE Saeed Mohammed Al Tayer, Chairman of the World Green Economy Organization (WGEO), said, “The World Green Economy Organization recognizes this urgency as it strives to facilitate a transition that is not only ecologically sustainable but also economically via

Blood Cancer: AOP Health Announces New Findings in Patients With Polycythemia Vera to Be Presented at the American Society of Hematology (ASH) 65 th Annual Meeting7.12.2023 16:57:00 CET | Press release

AOP Orphan Pharmaceuticals GmbH (AOP Health), Vienna, Austria, announced the results of an analysis assessing the impact of an individually optimized dosing regimen of ropeginterferon alfa-2b on treatment response in patients with low-risk polycythaemia vera (PV)1 These new data show that some low-risk PV patients require and can tolerate high ropeginterferon alfa-2b doses, and that the optimal dose varies substantially between patients. This press release features multimedia. View the full release here: Professor Heinz Gisslinger, MedUni Vienna/Austria (Fotocredit: IntMedCom) The first author of the abstract, Professor Heinz Gisslinger from the Medical University of Vienna/Austria, and his research team conducted the present analysis in the cohort of low-risk PV patients from the large trial PROUD-PV and its extension CONTINUATION-PV. The goal was to examine the impact of various baseline characteristics such as body mass index

O-RAN ALLIANCE Advances Technology Readiness Globally Through Fall 2023 PlugFest7.12.2023 16:37:00 CET | Press release

The O-RAN ALLIANCE, fulfilling its mission to transform Radio Access Networks to be open, intelligent, virtualized and fully interoperable, today announced the successful completion of the O-RAN ALLIANCE Global PlugFest Fall 2023. O-RAN Global PlugFests are periodic events organized and co-sponsored by O-RAN ALLIANCE to enable efficient progress of the O-RAN ecosystem through well-organized testing and integration. Vendors and providers come together to test, evaluate and verify their products and solutions. The O-RAN Global PlugFest Fall 2023 carried out critical testing and validation of O-RAN technologies to support and encourage ongoing adoption by the industry. The tests provided participants validation of O-RAN equipment conformance, performance and interoperability; tackled issues to overcome hurdles to wider technology adoption; and facilitated exploration of new features, scenarios and applications. Of note, two labs conducted field trials of O-RAN equipment, one in a rural en

GamesBeat and Xsolla Announce Global 2024 Tour Bringing Gaming Industry Insights and Diversity Initiatives to Cities Worldwide7.12.2023 16:00:00 CET | Press release

Xsolla, a global video game commerce company, is excited to announce its partnership with VentureBeat and GamesBeat, a premier source for tech news and events, for its upcoming 2024 Global Tour. The Global 2024 Tour brings an exciting series of events to cities worldwide. This press release features multimedia. View the full release here: (Graphic: Business Wire) This collaboration between Xsolla, and GamesBeat, marks a significant milestone in the gaming industry. The tour is set to kick off in Austin, Texas, at the renowned SXSW festival, showcasing a commitment to connecting industry leaders and enthusiasts from around the globe. The 2024 Global Tour promises to be a melting pot of ideas, featuring prominent figures from the gaming and tech industries. As the tour progresses, it will extend across four more locations including various cities in Europe and APAC, offering a dynamic platform for networking, knowledge sharing, an

Largest CSP project in the world inaugurated in Dubai7.12.2023 15:23:00 CET | Press release

His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, has inaugurated the largest concentrated solar power (CSP) project in the world, within the 4th phase of the Mohammed bin Rashid Al Maktoum Solar Park in Dubai. This press release features multimedia. View the full release here: Largest CSP project in the world inaugurated in Dubai (Photo: AETOSWire) His Highness Sheikh Mohammed bin Rashid Al Maktoum said: “The UAE has a clear vision to transform itself into one of the world's most sustainable nations. Our journey towards sustainability is comprehensive, encompassing advanced clean energy projects across diverse renewable sources, and innovative solutions integrated into various spheres of the economy and society. The Mohammed bin Rashid Al Maktoum Solar Park is at the heart of Dubai and the UAE’s commitment to create a world-class infrastructure for sustainabilit